Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile
Authors:
- 1 May 2014
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (5) , 2934-2937
Abstract
Fidaxomicin (FDX) is a narrow-spectrum antibiotic for the treatment of Clostridium difficile -associated diarrhea. While FDX and rifamycins share the same target (RNA polymerase), FDX exhibits a unique mode of action distinct from that of rifamycins. In comparative microbiological studies with C. difficile , FDX interacted synergistically with rifamycins, demonstrated a lower propensity for the development of resistance to rifamycins, and exhibited no cross-resistance with rifamycins. These results highlight differences in the mechanisms of action of FDX and rifamycins.Keywords
This publication has 25 references indexed in Scilit:
- Fidaxomicin inhibits toxin production in Clostridium difficileJournal of Antimicrobial Chemotherapy, 2012
- Fidaxomicin Inhibits Spore Production in Clostridium difficileClinical Infectious Diseases, 2012
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA SynthesisClinical Infectious Diseases, 2012
- Antimicrobial Activities of FidaxomicinClinical Infectious Diseases, 2012
- Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile InfectionClinical Infectious Diseases, 2012
- Divergent Rifamycin Susceptibilities of Clostridium difficile Strains in Canada and Italy and Predictive Accuracy of Rifampin Etest for Rifamycin ResistanceJournal of Clinical Microbiology, 2011
- A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infectionJournal of Antimicrobial Chemotherapy, 2011
- In Vitro Activities of OPT-80 and Comparator Drugs against Intestinal BacteriaAntimicrobial Agents and Chemotherapy, 2004
- Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic SpeciesAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity and Fecal Concentration of Rifaximin after Oral AdministrationAntimicrobial Agents and Chemotherapy, 2000